Preliminary Study of High Efficiency Vaccine of *Rhipicephalus (Boophilus) microplus* in South Xinjiang, China

Yong-Hong LIU, a, Kai-Rui LI, Bo HE, Fei LI, Lu-Yao ZHANG, Jiao-Jiao PAN, Qiang-Rong WANG, Li ZHAO

1 College of Animal Science, Tarim University, Aral 843300, P. R. CHINA
2 Animal Loimia Controlling and Diagnostic Center of Aksu Region, Aksu, Xinjiang 843300, P. R. CHINA
3 Animal husbandry and veterinary workstations of Barkol kazak autonomous county, Kumul 839200, P. R. CHINA

How to Cite This Article


Abstract

The direct damage and spread of pathogens of *Rhipicephalus (Boophilus) microplus* to cattle-based livestock is extremely serious, the traditional chemical acaricides control have many disadvantages, and vaccine prevention and control is a potential alternative. The commercially available vaccine, based on *Rhipicephalus (Boophilus) microplus* Bm86, has been favored by farmers and veterinarians in some areas, but it also has drawbacks such as reduced effectiveness due to genetic variation. Based on the fact that Bm91 and Bm86 sharing can enhance the immune effect of Bm86, as well as the characteristics of DNA vaccines, the combination of DNA vaccine and protein vaccine enhanced the immune effect. In this study, adopts the local *Rhipicephalus (Boophilus) microplus* strains, using prokaryotic expression system preparation Bm86 and Bm91 proteins, and using the eukaryotic expression vector pVAXI containing the CpG sequences constructed Bm86 and Bm91 double gene eukaryotic expression system. This research provides materials for the next step of Co-immunizing animals with Bm86 and Bm91 mixed proteins with Bm86 and Bm91 dual-gene carriers, it also provides a way for co-immunization with multi-antigen protein and multi-gene carriers to control ticks.

Keywords: *Rhipicephalus (Boophilus) microplus*, Bm86, Bm91, Co-expression

Çin’in Güney Xinjiang Bölgesinde *Rhipicephalus (Boophilus) microplus’a Karşı Yüksek Verimli Aşı İçin Ön Çalışma

Öz

Şığır besiciliğinde *Rhipicephalus (Boophilus) microplus’un* doğrudan oluşturduğu hasar ve yayılımı oldukça ciddi bir problem olup, geleneksel kımyasal akarisitlerin kontrolde pek çok dezavantajlı vardır ve aşı ile koruma ve kontrol alternatif olabilir. *Rhipicephalus (Boophilus) microplus* Bm86 temelli hazırlanan ve ticari olarak mevcut olan aşı bazı bölgelerde yetiştiriciler ve veteriner hekimler tarafından tercih edilmektedir, ancak genetik varyasyonlardan dolayı azalmış etkisi gibi negatif tarafları bulunmaktadır. Bm91 ve Bm86’ın birlikte bulunması Bm86’ın başlıca olumsuz etkisi artabilir. Bu çalışmada yerel *Rhipicephalus (Boophilus) microplus* türü ile Bm86 ve Bm91 proteinlerinin prokaryotik ekspresyon sistemi ve CpG sekansı içeren pVAX1 prokaryotik ekspresyon vektörü aracılı Bm86 ve Bm91 çift gen ökaryotik ekspresyon sistemi kullanılmıştır. Bu çalışma, Bm86 ve Bm91 proteinleri karışımı ile Bm86 ve Bm91 çift gen taşıyan aşı materisini oluşturmuştur, böylece kene kontrolünde çoklu antijen protein ve çoklu gen taşıyan aşı ile komünizasyon için bir araç oluşturulmuştur.

Anahtar sözcükler: *Rhipicephalus (Boophilus) microplus*, Bm86, Bm91, Koekspresyon

INTRODUCTION

The cattle tick *Rhipicephalus (Boophilus) microplus* is parasitic on cattle hematophagous ectoparasite, which spread of various pathogens. This parasite was found in West Africa, East Africa, South Africa, the Middle East, Latin America and Asia. In China, *R. microplus* tick is the most widespread tick species and widely distributed in 23 provinces. The traditional method to control *R. microplus* tick is to use chemical insecticides, but there are many disadvantages,
the cattle. The anti-tick effect of Bm91 on the immune response when inoculated to cattle will significantly reduce the weight and fecundity of female ticks. The main protective mechanism of this vaccine is the production of antibodies against Bm86 protein. This humoral immune response directly affects the intestinal tract of ticks, reduces the amount of blood sucking and reduces the weight and fecundity of female ticks. This antigen does not grant enough protection to several R. microplus tick populations. There is evidence that improving the efficacy of this vaccine against R. microplus tick has been achieved satisfactorily by adding more than one antigen into the vaccine. Bm 91 is an antigen isolated from the salivary glands and midgut of R. microplus tick. When inoculated to cattle, this antigen will significantly reduce the ability of sucking and laying eggs of ticks infesting the cattle. The anti-tick effect of Bm91 on the immune response against ticks is not as obvious as Bm86. But, Bm91 induced long-term immune response and showed an increased efficacy of Bm86 vaccine for R. microplus tick when co-administered. In addition, the sequence variation of antigen sites between R. microplus ticks isolated from different geographical areas have been proved to affect vaccine efficacy. Therefore, it is necessary to select the predominant strains in a local region for preparation of effective vaccines. The DNA vaccine has a potential advantage over other types of vaccines, they can induce strong cellular immune responses in addition to the humoral immune response, and they have no risks associated with the use of traditional attenuated vaccines, and the purification of plasmid DNA is easier and cheaper than recombinant protein. Furthermore, the DNA vaccine is stable at room temperature. At the same time, some studies have shown that the co-immunisation of DNA and protein vaccines boosts the immune effect.

From the above, this study investigated the preparation of Bm86 and Bm91 recombinant mixed proteins and dual gene plasmid DNA adopts the local Rhipicephalus (Boophilus) microplus strain, and laid the foundation for the joint immunological study to enhance the immunological effect of anti-tick vaccine.

**MATERIAL and METHODS**

Materials

Research Areas and R. microplus Collection

In 2013, R. microplus were collected from cows in Makit of Kashgar Prefecture, Xinjiang (1179 m above sea level; 38°54’N, E77°39’E). These tick specimens were placed in sampling vials with sufficient air and transported immediately to the laboratory for cryopreservation.

Methods

**RNA Extraction, RT-PCR and Sequence Analysis**

The cryopreserved R. microplus ticks specimens were washed twice with 0.1% DEPC, then frozen in liquid nitrogen and ground using a mortar. Total RNA was prepared from R. microplus ticks using TRIzol® reagent (BBI, Shanghai, China, Code No. B610409) in accordance with the manufacturers’ protocols. Total RNA was used for the synthesis of cDNA using the TaKaRa RNA PCR Kit (AMV) Ver.3.0 (Takara, Dalian, China, Code No. RR019A) in accordance with the manufacturer’s manual. The cDNA was used for R. microplus Bm86 (1953 bp) gene and Bm91 (1833 bp) gene amplification with gene-specific primers. The primers sequence used for Bm86 and Bm91 gene amplification were 5’-ATGGGCGTTGCCTGGGATCAG-3’; 5’-TTACACGGCAAGTGGGTG-3’ and 5’-ATGGCCTCCTTATAGAAGGC-3’; 5’-TGCGTGGCATCGCTTTGTTGTCGCAAGGAG-3’, the annealing temperature was 57ºC and 58 ºC, respectively. All PCR amplicons were bi-directionally sequenced using ABI PRISMTM 3730 XL DNA Analyzer. The sequencing results were analyzed in online BLAST (https://blast.ncbi.nlm.nih.gov/). The obtained sequences in this study were submitted to GenBank under the accession numbers ‘GenBank accession NO.: MH165269 and MH165270’.

**Vector Constructs for Expression Recombinant Protein**

The DNA fragments of Bm86 and Bm91 were amplified using the cryopreserved Bm86 and Bm91 gene amplification products using the Premix Taq™ Version 2.0 Kit (Takara, Dalian, China, Code No. R004A). The primers sequence used for Bm86 gene amplification were P1: 5’-ATGCGTGGCATCGCTTTGTTGTCGTAAGGAG-3’; 5’-TTACACGGCAAGTGGGTG-3’. The annealing temperature was 57ºC. The primers sequence used for Bm91 gene amplification were P2: 5’-ATGGCCTCCTTATAGAAGGC-3’; 5’-TGCGTGGCATCGCTTTGTTGTCGCAAGGAG-3’; the reaction enzyme sites EcoRI (I). The primers sequence used for Bm91 gene amplification were P3: 5’-TTCCCGGAATTCATGGCGTGGCATCGCTTTGTTGTCGTAAGGAG-3’; the reaction enzyme sites EcoRI (I). The primers sequence used for Bm91 gene amplification were P4: 5’-TTACACGGCAAGTGGGTG-3’. The annealing temperature was 57ºC.

From the above, this study investigated the preparation of Bm86 and Bm91 recombinant mixed proteins and dual gene plasmid DNA adopts the local Rhipicephalus (Boophilus) microplus strain, and laid the foundation for the joint immunological study to enhance the immunological effect of anti-tick vaccine.
and P4 for Bm91, P1 and P4 for Bm. The positive colony were cultured and extracted plasmids using the OMEGA™ Plasmid Mini Kit (OMEGA, China, Code No. D6943) in accordance with the manufacturer’s manual. The extracted plasmids were double-enzyme cut to identify, using the following restriction enzyme sites: BamHI and EcoRI for Bm86; EcoRI and NotI for Bm91; BamHI and NotI for Bm. Moreover, the vectors were verified by DNA sequencing. The DNA fragments of Bm86 and Bm91 were ligated into pET28a via the restriction enzyme sites BamHI and EcoRI and EcoRI/NotI using T4 DNA ligase. The plasmids were introduced into E. coli DH5α, the positive clone strains were detected by the technique of colony PCR, using the following primers: P1 and P2 for Bm86, P3 and P4 for Bm91. The positive colony were cultured and extracted plasmids using the OMEGA™ Plasmid Mini Kit (OMEGA, China, Code No. D6943) in accordance with the manufacturer’s manual. The extracted plasmids were double-enzyme cut to identify, using the following restriction enzyme sites: BamHI and EcoRI for Bm86; EcoRI and NotI for Bm91. The correct strain and plasmid DNA were kept for use.

**Expression and Purification of the Recombinant Protein**

The recombinant plasmid was confirmed by sequencing and introduced into E. coli expression strain BL21, the positive clone strains were detected by the technique of colony PCR, using the following primers: P1 and P2 for Bm86, P3 and P4 for Bm91. The positive colony were cultured and purified Bm86 and Bm91 protein by IPTG induction. E. coli cells harboring recombinant plasmids, pET28a-Bm86 and Bm91, were respectively grown under continuous shaking at 37°C in LB broth containing kanamycin. The cells were induced at OD600=0.5 with 0.6 mM IPTG, and grown for an additional 20 h at 18°C, and then harvested by centrifugation (5000 g, 15 min) and the pellets were frozen at −80°C until used. All purification steps were carried out at 4°C. Bacterial pellets were thawed in 100 mM lysis buffer (50 mM Tris-Cl, 200 mM NaCl, 1 mM DTT, 10% glycerine, 0.5% TritonX-100, 2 mM EDTA, pH 8.0), supplemented with the appropriate protease inhibitor cocktail (Roche, Switzerland). Bacterial cells were lysed using an ultrasonic processor to generate the crude bacterial extract and centrifuged for 30 min at 12,000 x g to collect the supernatant. The supernatants were passed over a Ni column (GE, USA) pre-equilibrated with binding buffer (NaH2PO4·2H2O 50 mM, NaCl 300 mM, Imidazole 10 mM, pH 8.0) and washed with 20 column volumes of binding buffer. Then the column was washed with 10 column volumes of washing buffer (NaH2PO4·2H2O 50 mM, NaCl 300 mM, Imidazole 20 mM, pH 8.0) and eluted with elution buffer (NaH2PO4·2H2O 50 mM, NaCl 300 mM, Imidazole 200 mM, pH 8.0). The proteins were quantified using BCA Protein Assay Kits in accordance with the manufacturer’s manual (GenStar, USA). Protein extracts (20 µg per lane) were resolved on 12% sodium dodecyl sulphate-polyacrylamide gels and electro blotted onto Bio-Rad Immobilon polyvinylidene fluoride (PVDF) membranes (Bio-Rad, USA). After transfer, PVDF membranes were blocked in Tris-buffered saline-Tween 20 (TBST; containing 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) containing 5% bovine serum albumin (Sigma-Aldrich) for 1 h at room temperature and incubated with the primary antibody of mouse His-TAG (Sigma-Aldrich, dilution 1:1000) overnight at 4°C. Membranes were washed three times (10 min) in TBST and incubated with the secondary antibody of anti-mouse immunoglobulin G (Sigma-Aldrich, dilution 1:2000) for 30 min. Subsequently, the membranes were washed three times (10 min) in TBST. Horseradish peroxidase activity was examined by Chemiluminescent Substrate (Roche) in accordance with the manufacturer’s protocol. The proteins were collected for the following experiment.

**Constructs for Eukaryotic Expression**

The full-length DNA fragment of Bm was inserted into pVX1-CpG vector between BamHI and NotI sites for cell transfection and subsequent injection into cattle -based livestock. Cell transfection was performed using HEK293 cells (CRL-1573, American Type Culture Collection). Briefly, HEK293 cells were cultured in petri dish with DMEM medium (HyClone, Code No.SH30243.01) added 10% FBS (Gemini, Code No.100-106) and 1% Penicillin-Streptomycin (Gibco, Code No.15140), put it in the incubator with 5% CO₂, 37°C. On the day before transfection, the cells are digested by trypsin, enriched by centrifugation or diluted with the medium according to their density, then replacing the medium using OPTI-MEM medium (Gibco, Code No.31985) with 10% FBS. Extracted 200 µL OPTI-MEM medium put into two 1.5 mL EP tubes, one EP tube added 4 µg plasmid DNA to be transfected, and another EP tube added 8 µL PEI (DNA: PEI=1 µg; 2 µL) gently mixed. The culture medium with PEI was added to the medium with the plasmid DNA, incubate at room temperature for 20 min. Add the HEK293 cells slowly to the mixture and gently mixed. The six orifice plates were cultured in the cell incubator, and the old medium was discarded after 4 h, and the new OPTI-MEM medium containing 10% FBS was added, then continued cultivation for 24 h before test.

Total RNA was prepared from transfection cells using TRIzol® reagent (Life Technologies, USA) and purified using a PureLink® RNA Mini Kit (Invitrogen, USA) combined with a PureLink® DNase Kit (Invitrogen), in accordance with the manufacturers’ protocols. RNA concentration and quality were measured using a NanoVue spectrophotometer (GE Healthcare, USA). Approximately 2 µg total RNA was used for the synthesis of cDNA using the TransScript One-Step gDNA Removal and cDNA Synthesis Kit in accordance with the manufacturer’s manual (TransGen, China). The cDNA was used for PCR reaction with gene-specific primers. The Bm fragment was amplified with P1 and P2 primers, and the pVX1-Bm-CpG is preserved to provide nucleic acid to immune animal.
RESULTS

To obtain the recombinant protein in *E. coli*, we separately developed the Bm86 and Bm91 prokaryotic expression vector pET28a (Fig. 1).

The field collected *R. microplus* ticks specimens were used for total RNA prepared. Total RNA was used for the synthesis of cDNA, and the cDNA was used for *R. microplus* Bm86 gene and Bm91 gene amplification with genespecific primers. The gene fragments that were consistent with the desired fragment size were obtained (Fig. 2). The PCR amplicons were bi-directionally sequenced, the sequencing results confirmed the Bm 86 gene with 1953 bp full open reading frame, encoding 650 aa and the Bm 91 gene with 1833 bp full open reading frame, encoding 610 aa, were obtained. The obtained Bm86 gene sequences results were similar with *B. microplus* cell surface glycoprotein Bm86 (GenBank accession NO.: TCKBM86A), and the similarity was 99% (1926/1953). The obtained Bm91 gene sequences results were similar with *Boophilus microplus* angiotensin-converting enzyme-like protein (Bm91) (GenBank accession NO: BMU62809), and the similarity was 98% (1801/1833).

Primers with internal *BamH* I and *EcoR* I restriction sites were designed to amplify the cDNA of Bm86, and Primers with internal *BamH* I and *Not* I restriction sites were designed to amplify the cDNA of Bm91. The PCR product was subcloned into the *BamHI*-*EcoRI* sites of pET28a to produce a fusion protein with a His tag at the N terminus, which was named as pET28a-Bm86 (Fig. 3). The PCR product was subcloned into the *BamH* I-*Not* I sites of pET28a to produce a fusion protein with a His tag at the N terminus, which was named as pET28a-Bm91 (Fig. 3).

*E. coli* cells harboring recombinant plasmids were used to express and purify The *R. microplus* Bm86 and Bm91 proteins. Bm86 contained a 650 amino acid, which was predicted as a 71.5 KDa polypeptide and Bm91 contained a 610 amino acid, which was predicted as a 67.1 KDa polypeptide were obtained (Fig. 4).
To further confirm the obtained proteins were the target proteins, the proteins were detected in the protein level with Western blot analyses (Fig. 5).

Co-immunization DNA and protein vaccines boosts the immune effect, so we investigated the preparation of Bm86 and Bm91 recombinant mixed proteins and dual gene plasmid DNA Bm. To obtain the dual gene plasmid DNA Bm, we developed the double gene expression vector pVAX1-Bm-CpG (Fig. 6).

Primers with internal BamH I and Not I restriction sites were designed to amplify the cDNA of Bm. The PCR product was subcloned into the BamHI-Not I sites of pVAX1-CpG to produce a double gene expression vector, which was named as pVAX1-Bm-CpG (Fig. 7).

To further study whether the double gene Bm could express in mammalian cells. The double gene expression vector of Bm was performed cell transfection using HEK293 cells. Total RNA was prepared from transfection cells and used for the synthesis of cDNA. The cDNA was used for PCR reaction with gene-specific primers P1 and P2. As shown in the Fig. 8, the target band can be detected, and the pVAX1-Bm-CpG is preserved to provide nucleic acid to immune animal.

**DISCUSSION**

Ticks rank second to mosquitoes, which are the pathogen carriers of human, livestock and wildlife diseases [2,40]. *Rhipicephalus (Boophilus) microplus* is the most influential
At present, the vaccines based on bm86 are used to immunize cattle in order to induce immunoglobulin. When ticks swallow blood, these antibodies, together with other components of the immune system, such as complement, can cause the cleavage of intestinal epithelial cells, causing ticks to die or damage. If Bm86 and Bm91 antigens used in combination, the effects of their antibodies will act on different parts of R. (B.) microplus ticks, and cause more serious damage, further reduce the fertility rate of ticks and the frequency of acaricide and achieve the result of control ticks and tick-borne diseases. Facts have been proved that the addition of the Bm91 antigen indeed improves the efficacy of Bm86 vaccine alone. In addition, the efficacy of the vaccination with Bm86 and the amino acid sequence variations in the Bm86 protein in challenges with R. microplus was negatively correlated. Therefore, using R. microplus ticks to prepare multi antigen vaccines may have an ideal effect on prevention and control of local ticks.

Gene vaccine or DNA vaccine, which is encoded antigen DNA, has been evaluated as prophylactic vaccines and therapeutic treatments for the treatment of infectious diseases, allergies or cancer. Studies have shown that pBMC2 DNA immunization potentially induces humoral and cellular immune responses against B. microplus. But, using Bm86 antigen vaccines did not achieve an ideal effect on prevention and control of B. microplus in sheep, due to Bm86 antigen induces a protective immune response against B. microplus, and DNA vaccination did not result in sustained antibody production. The effect of the B. microplus tick DNA vaccine and the double DNA vaccine of B. microplus tick immune bovine requires further verification. The combined use of different nucleic acid vaccines and recombinant protein vaccines immunization can enhance the humoral and cellular immune responses induced by DNA vaccine, such as raising antibody level, cell proliferation reaction, CTL activity and cytokine secretion, etc., so as to effectively improve the effect of the vaccine.

In addition, the expression vector of DNA vaccine is also important. The promoter strength of the expression vector is an important factor in determining the transcription efficiency, and the enhancer can promote the transcription ability of the promoter. PVAXI vector contains pCMV strong promoter and enhancer, which is an efficient new eukaryotic expression vector. Antigen gene expression unit and the CpG base motif adjuvant unit are two essential functional units of DNA vaccine. The CpG motif can induce the body to produce Th1 immune response and increase the expression of costimulatory molecules. In addition, in order to enhance the translation efficiency of eukaryotic genes, the kozak sequence (GCCACC) was increased at the front end of the antigen gene, which greatly improved the effect of DNA vaccine.

This study successfully expressed the R. microplus Bm86.
and Bm91 protein using the prokaryotic expression system, combined with the advantages of pVAX1 and CsP, successfully constructed the Bm86 and Bm91 dual gene carrier pVAX1-Bm-CsP, which provided the material for the next step of Co-immunizing animals with Bm86 and Bm91 mixed proteins and Bm86 and Bm91 dual-gene carriers, and laid the foundation for the development of the new vaccine. At present, the research progress is proceeding smoothly with the design of this study. It is expected that the double gene nucleic acid vaccine and the mixed protein vaccine have a good effect or provide the research ideas for the future development of the anti-tick vaccine.

CONSENT FOR PUBLICATION
Not applicable.

AVAILABILITY OF DATA AND MATERIALS
All the sequences obtained in our laboratory have been uploaded to the GenBank database (Bm86 and Bm91: MH165269 and MH165270).

COMPETING INTERESTS
The authors declare that they have no competing interests.

FUNDING
This study was funded by the National Natural Science Foundation of China (No. 31460655 and 31860698) and the open project of the Key Laboratory of Tarim Animal Husbandry Science and Technology, Xinjiang Production & Construction Corps (No. HS201501 and No. HS201801).

ETHICAL APPROVAL
Ethical treatment of animals was practiced in this study; however, the relevant document number is not available at Tarim University. Permission was obtained from the farm owners before collection of the specimens.

REFERENCES
Preliminary Study of High Efficiency ...